- Estimated deadline
- May 25, 2027
- Expected posting
- Apr 22, 2026
- Award size
- Not listed
- Total program funding
- Not listed
- Expected awards
- Not listed
- Cost sharing
- Not required
- Funding type
- Grant
- Category
- Health
Check this solicitation free
Grantee reads the full announcement and lists every required section, page limit, deadline, scoring criterion and compliance item. Takes about two minutes, no account needed.
About this opportunity
The National Center for Complementary and Integrative Health (NCCIH) intends to publish a Notice of Funding Opportunity (NOFO) to support collaborative interdisciplinary research that advances foundational understanding of non-addictive natural products for chronic pain management through a holistic, system-oriented approach. This initiative aligns with the NIH Helping to End Addiction Long-term (HEAL) Initiative by promoting safe, non-addictive, and prevention-oriented strategies for pain relief.
Chronic pain affects tens of millions of adults in the United States, contributing to disability, diminished quality of life, and significant healthcare costs. Despite widespread public use of natural products, such as botanicals, dietary supplements, and other naturally derived compounds for pain relief, scientific evidence has not kept pace with demand. Existing research often focuses on single molecular targets or isolated pathways, which fail to capture the complex, multisystem actions of these products.
The scope of natural products under this NOFO includes those commonly used by the public as well as those with emerging usage or therapeutic potential. Research is expected to take a holistic approach that examines how these products influence pain through coordinated biological pathways across the multiple organ systems, such as digestive, immune, vascular, musculoskeletal, lymphatic, metabolic/adipose tissues, and nervous system. Studies should also explore dose optimization based on the principle of hormesis, where low doses may elicit beneficial or adaptive effects while higher doses could be ineffective or harmful. In addition, investigators are encouraged to identify optimal intervention timing that aligns with the dynamic phases of pain and inflammation, thereby maximizing therapeutic outcomes and supporting physiological recovery.
This program emphasizes rigorous mechanistic studies that generate foundational insights to inform future translational research and guide the development of safe, evidence-based, non-addictive strategies for pain management.
Who can apply
- Public and Indian housing authorities
- For-profit organizations
- Small businesses
- Independent school districts
- State governments
- Public and state universities
- Private universities
- Other Native American tribal organizations
- Nonprofits with 501(c)(3) status
- Special district governments
- County governments
- Nonprofits without 501(c)(3) status
- City or township governments
- Federally recognized tribal governments
- Other (see eligibility)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Agency contact
Division of Extramural Research (DER) Program Officer
Please contact via e-mail.
- Reads the full solicitation and lays out every required section
- Drafts each section with you, in your words
- Checks the draft against every requirement before you submit
How to write it
All guidesMore from NIH
All NIH funding- Closes todayRFA-HG-27-011
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
Deadline Oct 30, 2026(0d)Up to $1.3M
- Closes todayRFA-HG-27-013
GREGoRi Innovation Projects (U01 Clinical Trial Optional)
Deadline Oct 30, 2026(0d)Up to $500K
- Closes todayRFA-HG-27-012
GREGoRi Technology Integration Center (U01, Clinical Trials Optional)
Deadline Oct 30, 2026(0d)Up to $2.3M
- Closes todayPAR-27-045
HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
Deadline Oct 30, 2026(0d)
- Closes in 3 daysPAR-24-280
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
Deadline Nov 2, 2026(3d)
- Closes in 3 daysPAR-24-279
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
Deadline Nov 2, 2026(3d)
Get new funding every Monday
New federal opportunities and upcoming deadlines for NIH and more, in one short email. Free, unsubscribe anytime.
Details from Grants.gov, last updated Apr 22, 2026. Deadlines and requirements can change: always confirm them in the official notice.